Quirk Erin has filed 3 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 75000 shares of Terns Pharmaceuticals, Inc. ($TERN) on January 23, 2024.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 23, 2024 | Terns Pharmaceuticals, Inc. | $TERN | Quirk Erin | President, Head of R&D | A | Common Stock | 75000 | $0.00 | 75,000.0000 | 71,259,239 | 9999.99% | 0.11% |
| Jan. 23, 2024 | Terns Pharmaceuticals, Inc. | $TERN | Quirk Erin | President, Head of R&D | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 71,259,239 | 9999.99% | 0.21% |
| Feb. 1, 2023 | Terns Pharmaceuticals, Inc. | $TERN | Quirk Erin | President, Head of R&D | A | Stock Option (Right to Buy) | 600000 | $0.00 | 600,000.0000 | 0 | 9999.99% | 0.00% |